---
title: "Aptevo Therap | 8-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280681840.md"
datetime: "2026-03-26T20:06:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280681840.md)
  - [en](https://longbridge.com/en/news/280681840.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280681840.md)
---

# Aptevo Therap | 8-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -87.27.

### Financial Results for the Year Ended December 31, 2025

#### Cash Position

Aptevo Therapeutics Inc. ended 2025 with $21.6 million in cash and cash equivalents, a significant increase from $8.7 million at December 31, 2024 .

#### Research and Development Expenses

Research and development expenses were $14.5 million for the year ended December 31, 2025, compared to $14.4 million for the year ended December 31, 2024 .

#### General and Administrative Expenses

General and administrative expenses increased to $11.8 million for the year ended December 31, 2025, up from $10.2 million in 2024 .

#### Other Income, Net

Other income, net, was $0.3 million for the year ended December 31, 2025, a decrease from $0.5 million in 2024 .

#### Net Loss Attributable to Common Shareholders

Aptevo Therapeutics Inc. reported a net loss of - $26.0 million for the year ended December 31, 2025, compared to a net loss of - $24.1 million in 2024 . Including a dividend, the net loss attributable to common shareholders for EPS purposes was - $27.5 million in 2025 .

### Balance Sheet Highlights (as of December 31, 2025)

#### Total Current Assets

Total Current Assets were $23.1 million, up from $10.7 million in 2024 .

#### Total Assets

Total Assets were $27.2 million, up from $15.6 million in 2024 .

#### Total Current Liabilities

Total Current Liabilities were $6.1 million, down from $6.2 million in 2024 .

#### Total Liabilities

Total Liabilities were $9.8 million, down from $10.8 million in 2024 .

#### Total Stockholders’ Equity

Total Stockholders’ Equity was $17.4 million, up from $4.8 million in 2024 .

### Operational Metrics (Clinical Performance)

Updated interim results for mipletamig in combination with ven/aza in 28 evaluable frontline AML patients showed an 86% clinical benefit rate, including a 79% CR/CRi remission rate and a 61% complete remission rate . Notably, 55% of patients achieving remission reached measurable residual disease–negative status, and 35% of remissions occurred in patients with TP53 mutations . No cytokine release syndrome has been observed in frontline patients treated to date .

### Outlook / Guidance

Aptevo Therapeutics Inc. expects its current resources to support operations into the fourth quarter of 2026 . The company established a $60 million equity line facility in 2026, which, if fully utilized alongside current resources, is expected to support operations into 2029 . This facility provides financing flexibility and allows the company to access capital opportunistically .

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)

## Related News & Research

- [Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategy](https://longbridge.com/en/news/293969770.md)
- [Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone | APVO Stock News](https://longbridge.com/en/news/293930096.md)
- [Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone](https://longbridge.com/en/news/293970382.md)
- [AbCellera partners with Vertex to develop multispecific T-cell engagers for autoimmune diseases, other conditions](https://longbridge.com/en/news/294196467.md)
- [Brandenburg Kapital portfolio firm 4TEEN4 wins FDA fast-track status for cardiogenic shock drug Invobenitug](https://longbridge.com/en/news/294323930.md)